title: rTMS effects on levodopa induced dyskinesias in Parkinson's disease patients: searching for effective cortical targets.
abstract: Long-term therapy with levodopa and dopamine agonists in Parkinson's disease (PD) patients is complicated by the development of fluctuations in motor response, such as levo-dopa induced dyskinesia (LID). Repetitive Transcranial Magnetic Stimulation (rTMS) has been recently put forward as a possible therapeutic tool able to LID in PD. Trains of 1 Hz rTMS applied either over the supplementary motor area (SMA) or the primary motor cortex (M1) were able to induce a transient reduction in the severity of LID, confirming that an over-activity of these areas plays a crucial role in the pathophysiology of LID. However, repeated sessions of rTMS were not effective in inducing persistent beneficial clinical effects. Functional or metabolic changes have been reported in the cerebellum in studies in PD patients treated with procedures known to alleviate LID, such as deep brain stimulation. Therefore, the effects of rTMS applied over the lateral cerebellum has been recently tested in patients with LID. A two-week course of bilateral cerebellar rTMS induced persistent clinical beneficial effects, reducing peak-dose LID for up to four weeks after the end of the daily stimulation period. These findings demonstrate that rTMS is a potential tool in individuating the best cortical targets and the optimal parameters of stimulation able to improve LID in dyskinetic PD patients.
authors: Laboratorio di Neurologia Clinica e Comportamentale, Fondazione Santa Lucia IRCCS, Rome, Italy Stroke Unit, Dipartimento di Neuroscienze, Policlinico Tor Vergata, Rome, Italy. g.koch@hsantalucia.it
authors: Giacomo
authors: G
authors: Koch
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D002531:Cerebellum / Q000473:pathology / Q000528:radiation effects; D002540:Cerebral Cortex / Q000473:pathology*; D004409:Dyskinesia, Drug-Induced / Q000628:therapy*; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D010300:Parkinson Disease / Q000150:complications*; D017397:Prefrontal Cortex / Q000473:pathology; D050781:Transcranial Magnetic Stimulation
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa